Top

BMC Cancer

Published in:

01-12-2021 | Myelodysplastic Syndrome | Review

The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

Authors: K. A. Mundt, L. D. Dell, P. Boffetta, E. M. Beckett, H. N. Lynch, V. J. Desai, C. K. Lin, W. J. Thompson

Published in: BMC Cancer | Issue 1/2021

Abstract

Introduction

Although myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) – including chronic myeloid leukemia (CML) – and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are largely clinically distinct myeloid malignancies, epidemiological studies rarely examine them separately and often combine them with lymphoid malignancies, limiting possible etiological interpretations for specific myeloid malignancies.

Methods

We systematically evaluated the epidemiological literature on the four chemical agents (1,3-butadiene, formaldehyde, benzene, and tobacco smoking, excluding pharmaceutical, microbial and radioactive agents, and pesticides) classified by the International Agency for Research on Cancer as having sufficient epidemiological evidence to conclude that each causes “myeloid malignancies.” Literature searches of IARC Monographs and PubMed identified 85 studies that we critically assessed, and for appropriate subsets, summarized results using meta-analysis.

Results

Only two epidemiological studies on 1,3-butadiene were identified, but reported findings were inadequate to evaluate specific myeloid malignancies. Studies on formaldehyde reported results for AML and CML – and not for MDS or MPN – but reported no increased risks. For benzene, several specific myeloid malignancies were evaluated, with consistent associations reported with AML and MDS and mixed results for CML. Studies of tobacco smoking examined all major myeloid malignancies, demonstrating consistent relationships with AML, MDS and MPN, but not with CML.

Conclusions

Surprisingly few epidemiological studies present results for specific myeloid malignancies, and those identified were inconsistent across studies of the same exposure, as well as across chemical agents. This exercise illustrates that even for agents classified as having sufficient evidence of causing “myeloid malignancies,” the epidemiological evidence for specific myeloid malignancies is generally limited and inconsistent. Future epidemiological studies should report findings for the specific myeloid malignancies, as combining them post hoc – where appropriate – always remains possible, whereas disaggregation may not. Furthermore, combining results across possibly discrete diseases reduces the chances of identifying important malignancy-specific causal associations.

Available only for authorised users

Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384–99. https://doi.org/10.1182/blood-2008-07-077982.CrossRefPubMedPubMedCentral

Linet MS, Morton LM, Devesa SS, Dores GM. Leukemias. In: Thun MJ, et al., editors. Schottenfeld and Fraumeni Cancer epidemiology and prevention. 4th ed. New York: Oxford University Press; 2018. p. 715–44.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51. https://doi.org/10.1182/blood-2009-03-209262.CrossRefPubMed

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.CrossRefPubMedPubMedCentral

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMed

International Agency for Research on Cancer (IARC) (2018) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Benzene. Volume 120. Lyon, France.

World Health Organization (2016) WHO classification of Tumours of Haematopoietic and lymphoid tissues, WHO classification of Tumours, revised 4th edition, volume 2. Geneva: World Health Organization.

Koeffler HP, Leong G. Preleukemia: one name, many meanings. Leukemia. 2017;31(3):534–42. https://doi.org/10.1038/leu.2016.364.CrossRefPubMedPubMedCentral

Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93(10):1267–91. https://doi.org/10.1002/ajh.25214.CrossRefPubMed

10.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.

11.

Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1–16.PubMedCrossRef

12.

Natelson EA. Benzene-induced acute myeloid leukemia: a clinician's perspective. Am J Hematol. 2007;82(9):826–30.PubMedCrossRef

13.

Mrózek K, Bloomfield CD. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr. 2008;(39):52–7. https://doi.org/10.1093/jncimonographs/lgn003.

14.

Blau O. Gene mutations in acute myeloid leukemia – incidence, prognostic influence, and association with other molecular markers. In: Guenova M, Balatzenko G, editors. Leukemias – updates and new insights. IntechOpen; 2015. https://doi.org/10.5772/60928.CrossRef

15.

Schieber M, Crispino JD, Stein B. Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J. 2019;9(9):74. https://doi.org/10.1038/s41408-019-0236-2.CrossRefPubMedPubMedCentral

16.

Helbig G. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. Med Oncol. 2018;35(9):119. https://doi.org/10.1007/s12032-018-1187-3.CrossRefPubMedPubMedCentral

17.

Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6(6):403–12. https://doi.org/10.1007/s13238-015-0143-7.CrossRefPubMedPubMedCentral

18.

NIH (2019) Chromosome 22. https://ghrnlmnihgov/chromosome/22 Reviewed: September 2016; Published: December 10, 2019. Accessed: 10 Dec 2019.

19.

Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Wild CP. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827–39. https://doi.org/10.1093/jnci/djr483.CrossRefPubMedPubMedCentral

20.

International Agency for Research on Cancer (IARC) (2019) List of classifications by cancer site with sufficient or limited evidence in humans, Volumes 1to 125. https://monographs.iarc.fr/wp-content/uploads/2019/07/Classifications_by_cancer_site.pdf. Accessed 10 Dec 2019.

21.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

22.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.100009.CrossRefPubMedPubMedCentral

23.

International Agency for Research on Cancer (IARC) (2012) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Chemical Agents and Related Occupations. Volume 100F. Lyon, France.

24.

Macaluso M, Larson R, Delzell E, Sathiakumar N, Hovinga M, Julian J, Muir D, Cole P. Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. Toxicology. 1996;113(1–3):190–202.PubMedCrossRef

25.

Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R, Delzell E. An updated study of mortality among north American synthetic rubber industry workers. Occup Environ Med. 2005;62(12):822–9.PubMedPubMedCentralCrossRef

26.

Cheng H, Sathiakumar N, Graff J, Matthews R, Delzell E. 1,3-butadiene and leukemia among synthetic rubber industry workers: exposure-response relationships. Chem Biol Interact. 2007;166(1–3):15–24.PubMedCrossRef

27.

Checkoway H, Lees PSJ, Dell LD, Gentry PR, Mundt KA. Peak exposures in epidemiologic studies and Cancer risks: considerations for regulatory risk assessment. Risk Anal. 2019;39(7):1441–64. https://doi.org/10.1111/risa.13294.CrossRefPubMedPubMedCentral

28.

Checkoway H, Boffetta P, Mundt DJ, Mundt KA. Critical review and synthesis of the epidemiologic evidence on formaldehyde exposure and risk of leukemia and other lymphohematopoietic malignancies. Cancer Causes Control. 2012;23(11):1747–66. https://doi.org/10.1007/s10552-012-0055-2.CrossRefPubMedPubMedCentral

29.

Meyers AR, Pinkerton LE, Hein MJ. Cohort mortality study of garment industry workers exposed to formaldehyde: update and internal comparisons. Am J Ind Med. 2013;56(9):1027–39. https://doi.org/10.1002/ajim.22199.CrossRefPubMed

30.

Coggon D, Ntani G, Harris EC, Palmer KT. Upper airway cancer, myeloid leukemia, and other cancers in a cohort of British chemical workers exposed to formaldehyde. Am J Epidemiol. 2014;179(11):1301–11. https://doi.org/10.1093/aje/kwu049.CrossRefPubMed

31.

Checkoway H, Dell LD, Boffetta P, Gallagher AE, Crawford L, Lees PS, Mundt KA. Formaldehyde exposure and mortality risks from acute myeloid leukemia and other Lymphohematopoietic malignancies in the US National Cancer Institute cohort study of Workers in Formaldehyde Industries. J Occup Environ Med. 2015;57(7):785–94. https://doi.org/10.1097/JOM.0000000000000466.CrossRefPubMed

32.

Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, Hauptmann M. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute cohort. J Natl Cancer Inst. 2009;101(10):751–61. https://doi.org/10.1093/jnci/djp096.CrossRefPubMedPubMedCentral

33.

Saberi Hosnijeh F, Christopher Y, Peeters P, Romieu I, Xun W, Riboli E, Raaschou-Nielsen O, Tjønneland A, Becker N, Nieters A, Trichopoulou A, Bamia C, Orfanos P, Oddone E, Luján-Barroso L, Dorronsoro M, Navarro C, Barricarte A, Molina-Montes E, Wareham N, Vineis P, Vermeulen R. Occupation and risk of lymphoid and myeloid leukaemia in the European prospective investigation into Cancer and nutrition (EPIC). Occup Environ Med. 2013;70(7):464–70.PubMedCrossRef

34.

Talibov M, Lehtinen-Jacks S, Martinsen JI, Kjærheim K, Lynge E, Sparén P, Ryggvadottir L, Weiderpass E, Kauppinen T, Kyyrönen P, Pukkala E. Occupational exposure to solvents and acute myeloid leukemia: a population-based, case-control study in four Nordic countries. Scand J Work Environ Health. 2014;40(5):511–7. https://doi.org/10.5271/sjweh.3436.CrossRefPubMed

35.

Pinkerton LE, Hein MJ, Stayner LT. Mortality among a cohort of garment workers exposed to formaldehyde: an update. Occup Environ Med. 2004;61(3):193–200.PubMedPubMedCentralCrossRef

36.

Pira E, Romano C, Verga F, La Vecchia C. Mortality from lymphohematopoietic neoplasms and other causes in a cohort of laminated plastic workers exposed to formaldehyde. Cancer Causes Control. 2014;25(10):1343–9. https://doi.org/10.1007/s10552-014-0440-0.CrossRefPubMed

37.

Adegoke OJ, Blair A, Shu XO, Sanderson M, Jin F, Dosemeci M, Addy CL. Zheng W (2003) occupational history and exposure and the risk of adult leukemia in Shanghai. Ann Epidemiol. 2003;13(7):485–94.PubMedCrossRef

38.

Albin M, Björk J, Welinder H, Tinnerberg H, Mauritzson N, Billström R, Strömberg U, Mikoczy Z, Johansson B, Ahlgren T, Nilsson PG, Mitelman F, Hagmar L. Cytogenetic and morphologic subgroups of myelodysplastic syndromes in relation to occupational and hobby exposures. Scand J Work Environ Health. 2003;29(5):378–87.PubMedCrossRef

39.

Blair A, Zheng T, Linos A, Stewart PA, Zhang YW, Cantor KP. Occupation and leukemia: a population-based case-control study in Iowa and Minnesota. Am J Ind Med. 2001;40(1):3–14.PubMedCrossRef

40.

Björk J, Albin M, Welinder H, Tinnerberg H, Mauritzson N, Kauppinen T, Strömberg U, Johansson B, Billström R, Mikoczy Z, Ahlgren T, Nilsson PG, Mitelman F, Hagmar L. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med. 2001a;58(11):722–7.PubMedPubMedCentralCrossRef

41.

Bonzini M, Grillo P, Consonni D, Cacace R, Ancona C, Forastiere F, Cocco PL, Satta G, Boldori L, Carugno M, Pesatori CA. Cancer risk in oil refinery workers: a pooled mortality study in Italy. Med Lav. 2019 Feb 22. 2019;110(1):3–10. https://doi.org/10.23749/mdl.v110i1.7842.CrossRefPubMedPubMedCentral

42.

Collins JJ, Anteau SE, Swaen GM, Bodner KM, Bodnar CM. Lymphatic and hematopoietic cancers among benzene-exposed workers. J Occup Environ Med. 2015;57(2):159–63. https://doi.org/10.1097/JOM.0000000000000324.CrossRefPubMed

43.

Copley GB, Schnatter AR, Armstrong TW, Irons RD, Chen M, Wang XQ, Kerzic P. Hospital-based case-control study of MDS subtypes and benzene exposure in Shanghai. J Occup Environ Med. 2017;59(4):349–55. https://doi.org/10.1097/JOM.0000000000000952.CrossRefPubMedPubMedCentral

44.

Costantini AS, Benvenuti A, Vineis P, Kriebel D, Tumino R, Ramazzotti V, Rodella S, Stagnaro E, Crosignani P, Amadori D, Mirabelli D, Sommani L, Belletti I, Troschel L, Romeo L, Miceli G, Tozzi GA, Mendico I, Maltoni SA, Miligi L. Risk of leukemia and multiple myeloma associated with exposure to benzene and other organic solvents: evidence from the Italian multicenter case-control study. Am J Ind Med. 2008;51(11):803–11. https://doi.org/10.1002/ajim.20592.CrossRefPubMed

45.

Divine BJ, Hartman CM, Wendt JK. Update of the Texaco mortality study 1947-93: part II. Analyses of specific causes of death for white men employed in refining, research, and petrochemicals. Occup Environ Med. 1999;56(3):174–80.PubMedPubMedCentralCrossRef

46.

Divine BJ, Hartman CM. Update of a study of crude oil production workers 1946-94. Occup Environ Med. 2000;57(6):411–7.PubMedPubMedCentralCrossRef

47.

Guénel P, Imbernon E, Chevalier A, Crinquand-Calastreng A, Goldberg M. Leukemia in relation to occupational exposures to benzene and other agents: a case-control study nested in a cohort of gas and electric utility workers. Am J Ind Med. 2002;42(2):87–97.PubMedCrossRef

48.

Huebner WW, Wojcik NC, Jorgensen G, Marcella SP, Nicolich MJ. Mortality patterns and trends among 127,266 U.S.-based men in a petroleum company: update 1979-2000. J Occup Environ Med. 2009;51(11):1333–48. https://doi.org/10.1097/JOM.0b013e3181be6c18.CrossRefPubMed

49.

Ireland B, Collins JJ, Buckley CF, Riordan SG. Cancer mortality among workers with benzene exposure. Epidemiology. 1997;8(3):318–20.PubMedCrossRef

50.

Kirkeleit J, Riise T, Bråtveit M, Moen BE. Increased risk of acute myelogenous leukemia and multiple myeloma in a historical cohort of upstream petroleum workers exposed to crude oil. Cancer Causes Control. 2008;19(1):13–23.PubMedCrossRef

51.

Linet MS, Yin SN, Gilbert ES, Dores GM, Hayes RB, Vermeulen R, Tian HY, Lan Q, Portengen L, Ji BT, Li GL, Rothman N, Chinese Center for Disease Control and Prevention-U.S. National Cancer Institute Benzene Study Group. A retrospective cohort study of cause-specific mortality and incidence of hematopoietic malignancies in Chinese benzene-exposed workers. Int J Cancer. 2015.

52.

McCraw DS, Joyner RE, Cole P. Excess leukemia in a refinery population. J Occup Med. 1985;27(3):220–2.PubMed

53.

Poynter JN, Richardson M, Roesler M, Blair CK, Hirsch B, Nguyen P, Cioc A, Cerhan JR, Warlick E. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. Int J Cancer. 2017;140(1):23–33. https://doi.org/10.1002/ijc.30420.CrossRefPubMed

54.

Rhomberg L, Goodman J, Tao G, Zu K, Chandalia J, Williams PR, Allen B. Evaluation of acute nonlymphocytic leukemia and its subtypes with updated benzene exposure and mortality estimates: a Lifetable analysis of the Pliofilm cohort. J Occup Environ Med. 2016;58(4):414–20. https://doi.org/10.1097/JOM.0000000000000689.CrossRefPubMed

55.

Rushton L, Schnatter AR, Tang G, Glass DC. Acute myeloid and chronic lymphoid leukaemias and exposure to low-level benzene among petroleum workers. Br J Cancer. 2014;110(3):783–7. https://doi.org/10.1038/bjc.2013.780.CrossRefPubMed

56.

Sathiakumar N, Delzell E, Cole P, Brill I, Frisch J, Spivey G. A case-control study of leukemia among petroleum workers. J Occup Environ Med. 1995;37(11):1269–77.PubMedCrossRef

57.

Satin KP, Wong O, Yuan LA, Bailey WJ, Newton KL, Wen CP, Swencicki RE. A 50-year mortality follow-up of a large cohort of oil refinery workers in Texas. J Occup Environ Med. 1996;38(5):492–506.PubMedCrossRef

58.

Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst. 2012;104(22):1724–37. https://doi.org/10.1093/jnci/djs411.CrossRefPubMedPubMedCentral

59.

Stenehjem JS, Kjærheim K, Bråtveit M, Samuelsen SO, Barone-Adesi F, Rothman N, Lan Q, Grimsrud TK. Benzene exposure and risk of lymphohaematopoietic cancers in 25,000 offshore oil industry workers. Br J Cancer. 2015;112(9):1603–12. https://doi.org/10.1038/bjc.2015.108.CrossRefPubMedPubMedCentral

60.

Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia. 2005;19(11):1912–8.PubMedCrossRef

61.

Teras LR, Diver WR, Deubler EL, Krewski D, Flowers CR, Switchenko JM, Gapstur SM. Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. Int J Cancer. 2019;145(10):2647–60. https://doi.org/10.1002/ijc.32202.CrossRefPubMed

62.

Wong O, Harris F, Smith TJ. Health effects of gasoline . II Mortality patterns of distribution workers in the United States exposure. Environ Health Perspect. 1993;101(Suppl 6):63–76.PubMedPubMedCentralCrossRef

63.

Wong O, Harris F, Rosamilia K, Raabe GK. An updated mortality study of workers at a petroleum refinery in Beaumont, Texas, 1945 to 1996. J Occup Environ Med. 2001a;43(4):384–401.PubMedCrossRef

64.

Wong O, Harris F, Rosamilia K, Raabe GK. Updated mortality study of workers at a petroleum refinery in Torrance, California, 1959 to 1997. J Occup Environ Med. 2001b;43(12):1089–102.PubMedCrossRef

65.

Wong O, Harris F, Armstrong TW, Hua F. A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of environmental and occupational risk factors by subtypes of the WHO classification. Chem Biol Interact. 2010;184(1–2):112–28. https://doi.org/10.1016/j.cbi.2009.10.017.CrossRefPubMed

66.

Linet MS, Gilbert ES, Vermeulen R, Dores GM, Yin SN, Portengen L, Hayes RB, Ji BT, Lan Q, Li GL, Rothman N, Chinese Center for Disease Control and Prevention–US National Cancer Institute Benzene Study Group. Benzene exposure response and risk of myeloid neoplasms in Chinese workers: a multicenter case-cohort study. J Natl Cancer Inst. 2019;111(5):465–74. https://doi.org/10.1093/jnci/djy143.CrossRefPubMed

67.

Sorahan T, Mohammed N 2016) Incidence of Myelodysplastic syndrome in UK petroleum distribution and oil refinery workers, 1995-2011. Int J Environ Res Public Health. 13(5). Pii: E474. doi: https://doi.org/10.3390/ijerph13050474.

68.

Schnatter AR, Wojcik NC, Jorgensen G. Mortality update of a cohort of Canadian petroleum workers. J Occup Environ Med. 2019;61(3):225–38. https://doi.org/10.1097/JOM.0000000000001523.CrossRefPubMed

69.

International Agency for Research on Cancer (IARC) (2012) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Personal Habits and Indoor Combustions. Volume 100E. Lyon, France.

70.

Avgerinou C, Giannezi I, Theodoropoulou S, Lazaris V, Kolliopoulou G, Zikos P, Alamanos Y, Leotsinidis M, Symeonidis A. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. Hematology. 2017;22(7):419–29. https://doi.org/10.1080/10245332.2016.1277006.CrossRefPubMed

71.

Batty GD, Kivimaki M, Gray L, Smith GD, Marmot MG, Shipley MJ. Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study. Ann Oncol. 2008;19(5):996–1002. https://doi.org/10.1093/annonc/mdm578.CrossRefPubMed

72.

Björk J, Albin M, Mauritzson N, Strömberg U, Johansson B, Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology. 2000;11(3):285–91.PubMedCrossRef

73.

Björk J, Albin M, Mauritzson N, Strömberg U, Johansson B, Hagmar L. Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose-response relations. Leuk Res. 2001b;25(10):865–72.PubMedCrossRef

74.

Björk J, Johansson B, Broberg K, Albin M. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study. Leuk Res. 2009;33(6):788–91. https://doi.org/10.1016/j.leukres.2008.10.009.CrossRefPubMed

75.

Brown LM, Gibson R, Blair A, Burmeister LF, Schuman LM, Cantor KP, Fraumeni JF Jr. Smoking and risk of leukemia. Am J Epidemiol. 1992;135(7):763–8.PubMedCrossRef

76.

Brownson RC, Chang JC, Davis JR. Cigarette smoking and risk of adult leukemia. Am J Epidemiol. 1991;134(9):938–41.PubMedCrossRef

77.

Dalamaga M, Petridou E, Cook FE, Trichopoulos D. Risk factors for myelodysplastic syndromes: a case-control study in Greece. Cancer Causes Control. 2002;13(7):603–8.PubMedCrossRef

78.

Fernberg P, Odenbro A, Bellocco R, Boffetta P, Pawitan Y, Zendehdel K, Adami J. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res. 2007;67(12):5983–6.PubMedCrossRef

79.

Ido M, Nagata C, Kawakami N, Shimizu H, Yoshida Y, Nomura T, Mizoguchi H. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res. 1996;20(9):727–31.PubMedCrossRef

80.

Kabat GC, Augustine A, Hebert JR. Smoking and adult leukemia: a case-control study. J Clin Epidemiol. 1988;41(9):907–14.PubMedCrossRef

81.

Kabat GC, Wu JW, Moore SC, Morton LM, Park Y, Hollenbeck AR, Rohan TE. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study. Cancer Epidemiol Biomark Prev. 2013;22(5):848–54. https://doi.org/10.1158/1055-9965.EPI-13-0093.CrossRef

82.

Kane EV, Roman E, Cartwright R, Parker J. Morgan G (1999) tobacco and the risk of acute leukaemia in adults. Br J Cancer. 1999 Dec;81(7):1228–33.PubMedPubMedCentralCrossRef

83.

Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16(5):489–500.PubMedCrossRef

84.

Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V; Million Women Study Collaborators. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK million women study. Br J Cancer. 2012;107(5):879–87. https://doi.org/10.1038/bjc.2012.333.CrossRef

85.

Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Virnig BA, Cerhan JR. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's health study cohort. Int J Cancer. 2014;134(7):1741–50. https://doi.org/10.1002/ijc.28492.CrossRefPubMed

86.

Linet MS, McLaughlin JK, Hsing AW, Wacholder S, Co-Chien HT, Schuman LM, Bjelke E, Blot WJ. Cigarette smoking and leukemia: results from the Lutheran brotherhood cohort study. Cancer Causes Control. 1991;2(6):413–7.PubMedCrossRef

87.

Lv L, Lin G, Gao X, Wu C, Dai J, Yang Y, Zou H, Sun H, Gu M, Chen X, Fu H, Bao L. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. Am J Hematol. 2011;86(2):163–9. https://doi.org/10.1002/ajh.21941.CrossRefPubMed

88.

Ma X, Lim U, Park Y, Mayne ST, Wang R, Hartge P, Hollenbeck AR, Schatzkin A. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol. 2009;169(12):1492–9. https://doi.org/10.1093/aje/kwp074.CrossRefPubMedPubMedCentral

89.

Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, Schatzkin A, Cross AJ. Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. Am J Epidemiol. 2010;171(3):312–22. https://doi.org/10.1093/aje/kwp371.CrossRefPubMed

90.

Mele A, Szklo M, Visani G, Stazi MA, Castelli G, Pasquini P, Mandelli F. Hair dye use and other risk factors for leukemia and pre-leukemia: a case-control study. Italian leukemia study group. Am J Epidemiol. 1994;139(6):609–19.PubMedCrossRef

91.

Mills PK, Newell GR, Beeson WL, Fraser GE, Phillips RL. History of cigarette smoking and risk of leukemia and myeloma: results from the Adventist health study. J Natl Cancer Inst. 1990;82(23):1832–6.PubMedCrossRef

92.

Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 2013;37(4):410–6. https://doi.org/10.1016/j.canep.2013.03.012.CrossRefPubMed

93.

Nagata C, Shimizu H, Hirashima K, Kakishita E, Fujimura K, Niho Y, Karasawa M, Oguma S, Yoshida Y, Mizoguchi H. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res. 1999;23(1):57–62.PubMedCrossRef

94.

Nisse C, Haguenoer JM, Grandbastien B, Preudhomme C, Fontaine B, Brillet JM, Lejeune R, Fenaux P. Occupational and environmental risk factors of the myelodysplastic syndromes in the north of France. Br J Haematol. 2001;112(4):927–35.PubMedCrossRef

95.

Parodi S, Merlo DF, Stagnaro E, Working Group for the Epidemiology ofHematolymphopoietic Malignancies in Italy. Coffee and tea consumption and risk of leukaemia in an adult population: a reanalysis of the Italian multicentre case-control study. Cancer Epidemiol. 2017;47:81–7. https://doi.org/10.1016/j.canep.2017.01.005.CrossRefPubMed

96.

Pasqualetti P, Festuccia V, Acitelli P, Collacciani A, Giusti A, Casale R. Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol. 1997;97(3):659–62.PubMedCrossRef

97.

Pedersen KM, Bak M, Sørensen AL, Zwisler AD, Ellervik C, Larsen MK, Hasselbalch HC, Tolstrup JS. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. Cancer Med. 2018;7(11):5796–802. https://doi.org/10.1002/cam4.1815.CrossRefPubMedPubMedCentral

98.

Pekmezovic T, Suvajdzic Vukovic N, Kisic D, Grgurevic A, Bogdanovic A, Gotic M, Bakrac M, Brkic N. A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro). Ann Hematol. 2006;85(8):514–9.PubMedCrossRef

99.

Pogoda JM, Preston-Martin S, Nichols PW, Ross RK. Smoking and risk of acute myeloid leukemia: results from a Los Angeles County case-control study. Am J Epidemiol. 2002;155(6):546–53.PubMedCrossRef

100.

Richardson DB, Terschüren C, Pohlabeln H, Jöckel KH, Hoffmann W. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control. 2008;19(1):43–50.PubMedCrossRef

101.

Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JO, Schiffer CA, et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst. 1993;85(24):1994–2003.PubMedCrossRef

102.

Severson RK, Davis S, Heuser L, Daling JR, Thomas DB. Cigarette smoking and acute nonlymphocytic leukemia. Am J Epidemiol. 1990;132(3):418–22.PubMedCrossRef

103.

Speer SA, Semenza JC, Kurosaki T, Anton-Culver H. Risk factors for acute myeloid leukemia and multiple myeloma: a combination of GIS and case-control studies. J Environ Health. 2002;64(7):9–16.PubMed

104.

Stagnaro E, Ramazzotti V, Crosignani P, Fontana A, Masala G, Miligi L, Nanni O, Neri M, Rodella S, Costantini AS, Tumino R, Viganò C, Vindigni C, Vineis P. Smoking and hematolymphopoietic malignancies. Cancer Causes Control. 2001;12(4):325–34.PubMedCrossRef

105.

Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer. 2012;118(18):4589–96. https://doi.org/10.1002/cncr.27442.CrossRefPubMed

106.

Ugai T, Matsuo K, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Tsugane S, Japan Public Health Center-based Prospective Study Group. Smoking and subsequent risk of leukemia in Japan: the Japan public health center-based prospective study. J Epidemiol. 2017a;27(7):305–10. https://doi.org/10.1016/j.je.2016.07.005.CrossRefPubMedPubMedCentral

107.

Ugai T, Matsuo K, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Kanda Y, Tsugane S, Japan Public Health Centre-based Prospective Study Group. Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan public health Centre-based prospective study. Br J Haematol. 2017b;178(5):747–55. https://doi.org/10.1111/bjh.14749.CrossRefPubMed

108.

Wakabayashi I, Sakamoto K, Masui H, Yoshimoto S, Kanamaru A, Kakishita E, Hara H, Shimo-oku M, Nagai K, Shimo-oka M [corrected to Shimo-oku M] (1994) A case-control study on risk factors for leukemia in a district of Japan. Intern Med 33(4):198–203.

109.

West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res. 1995;19(2):127–39.PubMedCrossRef

110.

Wong O, Harris F, Yiying W, Hua F. A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol. 2009;55(3):340–52. https://doi.org/10.1016/j.yrtph.2009.08.007.CrossRefPubMed

111.

Xu X, Talbott EO, Zborowski JV, Rager JR. Cigarette smoking and the risk of adult leukemia: results from the three Mile Island cohort study. Arch Environ Occup Health. 2007;62(3):131–7. https://doi.org/10.3200/AEOH.62.3.131-137.CrossRefPubMed

112.

Mundt KA, Gentry PR, Dell LD, Rodricks JV, Boffetta P. Six years after the NRC review of EPA's draft IRIS toxicological review of formaldehyde: regulatory implications of new science in evaluating formaldehyde leukemogenicity. Regul Toxicol Pharmacol. 2018;92:472–90. https://doi.org/10.1016/j.yrtph.2017.11.006.CrossRefPubMed

Title: The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens
Authors: K. A. Mundt
L. D. Dell
P. Boffetta
E. M. Beckett
H. N. Lynch
V. J. Desai
C. K. Lin
W. J. Thompson
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Leukemia
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-07908-3

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma

Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013

Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols

Survival in endometrial cancer in relation to minimally invasive surgery or open surgery – a Swedish Gynecologic Cancer Group (SweGCG) study

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis

Actual long-term survival after resection of stage III soft tissue sarcoma